Sunday, 22 November 2026 SEC EDGAR filings, as they land
ALFAFINDER USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

Erasca Reports 69% Response Rate in Pancreatic Cancer Trial, Accelerates Phase 3

Erasca announced high response rates for its pan-RAS molecular glue in pancreatic cancer and non-small cell lung cancer trials. These clinical results have prompted the company to accelerate its Phase 3 trial timeline for first-line pancreatic cancer to the first half of 2027.

Contagious, coronavirus, deadly flu, diagnosis. Stock photo illustrating Erasca's other story.
Erasca, Inc. · Healthcare · Photo: Gam-Ol / Pixabay

Key highlights

  • Confirmed 69% objective response rate in patients with KRAS G12D or G12V pancreatic cancer
  • Reported 60% confirmed objective response rate in KRAS-mutant non-small cell lung cancer at 32 mg QD
  • Accelerated initiation of Phase 3 trial in first-line pancreatic cancer to H1 2027
  • Maintained 100% median relative dose intensity at the 32 mg pharmacologically active dose
  • Initial data for pan-KRAS inhibitor ERAS-4001 supports potential combination therapy with ERAS-0015

Phase 1 Clinical Results

Erasca disclosed updated interim results from its AURORAS-1 Phase 1 trial evaluating ERAS-0015, a pan-RAS molecular glue. In patients with KRAS G12D or G12V mutant pancreatic ductal adenocarcinoma treated at 32 mg once daily, the drug achieved a 69% confirmed objective response rate. Among the 13 patients in this subset, 77% had previously received at least three lines of therapy. Furthermore, the monotherapy showed a 60% objective response rate in KRAS-mutant non-small cell lung cancer. The safety profile remained favorable, with 100% median relative dose intensity and no treatment-related discontinuations at the 32 mg dose level.

Erasca, Inc. share price · last month
Line chart of Erasca, Inc.'s share price over the last month, from $14.49 on 21 Oct → $13.61 on 20 Nov; our story on 20 Nov at $14.22.

Down 4.3% since our story on 20 Nov: $14.22 when we broke it → $13.61 at the close on 20 Nov. Daily closing prices. Source: Yahoo Finance.

Show the prices
21 Oct$14.49
22 Oct$14.04
23 Oct$14.39
26 Oct$14.99
27 Oct$15.22
28 Oct$15.12
29 Oct$14.98
30 Oct$14.35
2 Nov$14.05
3 Nov$14.64
4 Nov$14.91
5 Nov$13.27
6 Nov$14.41
9 Nov$15.61
10 Nov$15.48
11 Nov$16.80
12 Nov$15.78
13 Nov$15.66
16 Nov$15.11
17 Nov$13.89
18 Nov$13.76
19 Nov$14.22
20 Nov$13.61

Strategic Development Timeline

The clinical data supports a significant shift in Erasca development timeline. The company is now accelerating the initiation of a Phase 3 trial for first-line pancreatic cancer, targeting the first half of 2027. This move leverages the high response rates observed in heavily pre-treated populations to move into earlier treatment lines. Additionally, initial data for ERAS-4001, a pan-KRAS inhibitor, showed encouraging monotherapy activity. Erasca intends to combine ERAS-4001 with ERAS-0015, potentially creating a vertical inhibition strategy to address RAS-mutant solid tumors that currently have limited precision medicine options.

Business Overview

Erasca is a clinical-stage precision oncology company focused on discovering and developing therapies for patients with RAS-mutant cancers. The company mission is to target the RAS-MAPK pathway, which is one of the most frequently mutated pathways in human oncology. Their pipeline includes multiple programs designed to inhibit various nodes of this pathway, including pan-RAS molecular glues and pan-KRAS inhibitors. Headquartered in San Diego, the company utilizes a structure-based drug discovery approach to identify small molecules that can bind to difficult-to-target proteins like KRAS, which was historically considered undruggable by the pharmaceutical industry.

Industry Landscape

The market for RAS-mutant cancer therapies is undergoing rapid evolution as the biotechnology sector moves beyond specific G12C inhibitors toward pan-RAS solutions. Pancreatic cancer remains a particularly challenging indication, with KRAS mutations present in approximately 90% of cases and a five-year survival rate that is among the lowest in oncology. Current standard-of-care treatments for first-line pancreatic cancer typically involve intensive chemotherapy regimens like gemcitabine plus nab-paclitaxel. Erasca pursuit of a molecular glue that targets multiple RAS isoforms could provide a more targeted alternative or a complementary treatment to these traditional cytotoxic therapies.

Erasca, Inc. · financial snapshot
Share price$14.22
Market cap$5.0B
1-month price change-2.74%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by Erasca, Inc. announcing updated Phase 1 clinical data and an accelerated Phase 3 trial timeline.

Read the filing ↗

Track Erasca, Inc. live

Get the next Erasca, Inc. SEC filing seconds after it lands.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.